Srdan Verstovsek, MD, PhD

Articles

Dr. Verstovsek on the Benefit of JAK Inhibitor Combos in Myelofibrosis

October 13th 2021

Srdan Verstovsek, MD, PhD, discusses the benefit of drug combinations to improve anemia in patients with myelofibrosis.

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10th 2021

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

Dr. Verstovsek on Efficacy of Pelabresib Plus Ruxolitinib in Myelofibrosis

July 19th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of the combination of pelabresib plus ruxolitinib in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Efficacy of Pacritinib in Myelofibrosis

June 17th 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy demonstrated with pacritinib in the treatment of patients with myelofibrosis.

Dr. Verstovsek on the Rationale for Utilizing Ruxolitinib/Navitoclax in Relapsed/Refractory Myelofibrosis

May 21st 2021

Srdan Verstovsek, MD, PhD, discusses the rationale for utilizing ruxolitinib and navitoclax in patients with relapsed/refractory myelofibrosis.

Dr. Verstovsek on Future Research Efforts in MPNs

May 18th 2021

Srdan Verstovsek, MD, PhD, discusses future research efforts for patients with myeloproliferative neoplasms.

Dr. Verstovsek on Real-World Survival Data With Ruxolitinib in Myelofibrosis

May 10th 2021

Srdan Verstovsek, MD, PhD, discusses real-world survival data with ruxolitinib in myelofibrosis.

Dr. Verstovsek on the Efficacy of Ruxolitinib Plus CPI-0610 in Myelofibrosis

May 3rd 2021

Srdan Verstovsek, MD, PhD, discusses the efficacy of ruxolitinib in combination with CPI-0610 in myelofibrosis.

Dr. Verstovsek on the Potential Utility of Luspatercept in Myelofibrosis

April 15th 2021

Srdan Verstovsek, MD, PhD, discusses the potential clinical utility of luspatercept-aamt in myelofibrosis.

Dr. Verstovsek on the Role of Prognostication in Myelofibrosis

April 7th 2021

Srdan Verstovsek, MD, PhD, discusses the role of prognostication in myelofibrosis.

Dr. Verstovsek on the Use of Luspatercept to Treat Anemia Associated With Myelofibrosis

February 16th 2021

Srdan Verstovsek, MD, PhD, discusses the use of luspatercept to treat anemia associated with myelofibrosis.

Dr. Verstovsek on the Role of Ruxolitinib in Myelofibrosis

December 16th 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

Dr. Verstovsek on the Results of the PV-AIM trial in Polycythemia Vera

December 5th 2020

Srdan Verstovsek, MD, PhD, discusses findings from the PV-AIM trial in polycythemia vera.

Dr. Verstovsek on the Different Phases of MPNs

October 6th 2020

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Dr. Verstovsek on the MANIFEST Trial With CPI-0610 in Myelofibrosis

August 29th 2020

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Dr. Verstovsek on the Rationale Behind Treating Myelofibrosis With CPI-0610/Ruxolitinib

July 13th 2020

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

July 1st 2020

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

Dr. Verstovsek on Toxicity Profile of Ruxolitinib in MPNs

February 22nd 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the toxicity profile of ruxolitinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Verstovsek on Benefit of Ruxolitinib in Polycythemia Vera

January 31st 2019

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses the benefit of ruxolitinib in polycythemia vera.

Dr. Verstovsek on JAK Inhibition in Polycythemia Vera

November 26th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.